anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To provide the titled preparation effective in preventing side effect caused by overdose at the initial stage of application and exhibiting continuous pharmacological effect over a long period, by partially covering a tacky surface of a drug-containing pressure-sensitive adhesive layer with a layer of a drug- permeable substance. CONSTITUTION:A surface of a film- or sheet-formed carrier is coated with a drug-containing pressure-sensitive adhesive layer produced by adding 0.05-40wt% drug for transcutaneous absorption to an pressure-sensitive adhesive such as acrylic adhesive, rubbery adhesive, etc. (the amount of the drug per unit area of the preparation is 2-800mug/cm&lt;2&gt;). The sticky surface is partially covered with a layer of a drug-permeable substance free from drug, preferably a substance having lower diffusion coefficient than the above adhesive layer. The covered area is 5-80%, preferably 10-50% of the total area. Preferably, the thickness of the adhesive layer is 10-100mum, that of the drug-permeable layer is 1-50mum and sum of both layers is 10-100mum.
PURPOSE:To provide a technology for making fish-and-shellfish peptides represented by mackerel peptide odorless or virtually odorless, and to provide an external or internal preparation incorporated with the resultant odorless or low-odoriferous component. CONSTITUTION:Water is added to fish-and-shellfish peptides obtained by enzymatic chemical modification of fish-and-shellfish proteins such as of mackerel followed by mixing under agitation and then conducting centrifugation, and the resulting supernatant is separated and then either dialyzed or put to ultrafiltration to eliminate low-molecular weight components, thus obtaining the odorless or low-odoriferous component 600-10000 in molecular weight. The above centrifugation and dialysis or ultrafiltration is made at &lt;=15 deg.C. After the dialysis or ultrafiltration, purification may be made using an adsorbent. The other external preparation (e.g. cosmetic, quasidrug) or internal preparation (e.g. beverage, food, medicine) can be obtained by incorporating the original preparation with the above odorless or low-odoriferous component.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, particularly to gynaecology and urology, and concerns treating chronic recurrent urogenital bacterial and viral infections. That is ensured by producing lymphocyte self-cells of the patient&#39;s blood. Then said lymphocytes are cultivated with an immunomodulator. It is followed with intrauterine introduction of 0.5-2.0 ml of a lymphocyte suspension in an acceptable medium at their concentration 106-107 cel/ml. ^ EFFECT: without using antibacterial preparations, method provides evident antiviral and antibacterial effects, normalisation of the immune status with minimum by-effects. ^ 5 cl, 4 ex, 3 tbl
PURPOSE:To provide the titled ceramic material composed of a ceramic material attached to a substrate sheet such as Japanese paper, plastic sheet, etc. having a specific thickness, and capable of forming a beautiful opaque layer having uniform thickness without necessitating skilled labor, only by pressing the composite sheet to the surface of a dental crown material, and baking the material. CONSTITUTION:Ceramic powder such as opaque powder is supplied from the tank 1, kneaded with water or an organic solvent to obtain the slurry 2, and stored in the slurry tank 3. The slurry 2 is applied to one surface of the substrate sheet S composed of an organic material such as Japanese paper, plastic sheet, etc. having a thickness of &lt;=1mm. (preferably about 0.5mm.) and delivered along the direction of the arrow by the rotation of the roller 4. The substrate applied with the ceramic slurry is if necessary passed through the vibration or pressing roll 7 to obtain a ceramic sheet T composed of the ceramic material C laminated to the substrate sheet at a thickness of 0.01-1.0mm.. The ceramic material T is cut to a shape sufficient to cover the whole circumference of the dental crown material D, attached to the surface of the material D and pressed closely to the surface of the crown material D. The sheet S is released from the product leaving the ceramic C on the surface of the dental corwn, and the ceramic C is baked to obtain the objective dental crown.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an IgE production inhibitor and IgE production-inhibiting food and beverage that can be expected to have excellent antiallergic action and also to provide an antiallergic agent and antiallergic food and beverage.  &lt;P&gt;SOLUTION: The IgE production inhibitor that includes Bifidobacterium catenulatum as an active ingredient. The IgE production inhibiting food and beverage that includes the IgE production inhibiting agent. The antiallergic agent that includes Bifidobacterium catenulatum as an active ingredient. The antiallergic food or beverage that includes the antiallergic agent.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
A wiping article is provided which includes an effervescent cleanser composition held within a sachet, at least one wall of the sachet including at least one pleat. The presence of pleats allows expansion room within the sachet to accommodate effervescent action. It also results in an ergonomically pleasant pillow configuration. Advantageously, the sachet is formed of two sheets with the second sheet being relatively more rigid than the first sheet and non-pleated which permits easier graspability by a user&#39;s hand. Additionally, at least one of the sheets should be water permeable. In a preferred embodiment, the effervescent composition is an intimate mixture of an acid material such as citric acid and an alkaline material such as sodium bicarbonate. Water contact causes the combination to effervesce. Skin benefit agents may be included within the composition.
The separation of ionisable or polarisable, carrier-free radionuclides from a liquid or liquefiable target material with low electrical conductivity is achieved by electro-fixation at one of the electrodes in a flow cell (1) with a permanent electrode arrangement (2,3). The fixing voltage is maintained during the separation. The fixed nuclide is removed from the target liquid after switching off or reversing the polarity of the electric field possibly after rinsing.  Also claimed is a flow cell for carrying out the separation, and the application of the process for radioisotopic tagging of organic cpds. with &lt;18&gt;F by nucleophilic substitution. The electrodes (2,3) have inert non-porous surfaces pref. made of Pt. The vessel wall (3) forms the cylindrical electrode, surface area at least 3 cm&lt;2&gt;, for the electro-fixation, and a coaxial field is applied. The liquid is fed into the cell through the axial electrode formed as a capillary. Field strengths of 10-100 V/cm are used. Dissolution of the nuclide from the electrode takes place with warming. The liquid is expelled from the flow cell using He. The separation unit is built into the line between the irradiation station and the reaction chamber where the radio-tracer cpds. are prepared.
Composition based on, at least, a cellulose derivative that comprises ester groups of cellulose, being part of them formiato groups, which can form fibers or films with the following properties. A) degree of substitution gs of the cellulose are formiato groups at least 2 percent and degree of polymerization gp of the cellulose, higher than 150 and less than 1,500. B) t&gt; 20 and mi&gt; 1,000; being the tenacity and my initial module of the fiber in cn/tex. C) is constituted by superposed layers around the axle of the filament, variing the optical direction and recristalization in each lay into a pseudoperiodic way throughout the axis. D) delta n&gt; 0.03; being deltan the birthfringency. Dissolution procedure to obtain the composition. (Machine-translation by Google Translate, not legally binding)
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, in particular to ophthalmology and deals with treatment of dystrophic diseases of posterior eye pole. For this purpose dissection of conjunctiva and separation of Tenon&#39;s capsule to posterior eye pole are performed. Into area of optic nerve successively introduced are 10% solution of trichloroacetic acid and crystalline talc. After 10-14 days into area of optic nerve retrobulbarly introduced are 0.5-0.8 ml of suspension of autologous macrophages, obtained from monocytes of patient&#39;s peripheral blood, in concentration (1.5-6.5)ù106 live cells/ml. Procedure of macrophage suspension introduction is repeated after three and six months. ^ EFFECT: method increases treatment efficiency due to improvement of blood circulation in area of posterior eye pole with stimulation of reparative processes in affected optic fibres. ^ 3 cl, 2 ex
A method and kit for the sequential early introduction to an infant of at least nine allergens to decrease the infant&#39;s risk for developing allergies. The method and kit includes an initial lower exposure dose of a first allergen to be taken for a day or two, followed by a higher maintenance dose of the first allergen to be taken for a day or more. Additional allergens are added, each first at an initial lower dose for a day or more followed by a higher maintenance dose for a day or more. This patent continues until all nine allergens are being given to an infant at their maintenance doses. The allergens can be provided in powdered protein form in premeasured pouches for addition to baby formula/mother&#39;s milk. Alternatively, the allergens can be included in baby formula, or in other foods such as snack bars, cookies, or gels.
PURPOSE:To produce titled glass adequate as a dental material without generation of voids, cracks, etc. and with good spread of a melt to a casting mold by incorporating an Li2O component and F atoms to the compsn of a ternary component system of CaO-Al2O3-P2O5. CONSTITUTION:This crystallized CaO-Al2O3-P2O5 glass is formed by incorporating 0.01-5pts.wt. Li2O and &lt;=3pts.wt. F atoms by 100pts.wt. in total of 10-60wt% CaO, 5-35wt% Al2O3 and 25-85wt% P2O5 into CaO-Al2O3-P2O5 stock composed of the respective above-mentioned compsn. The solubility of Al2O3 is improved by incorporating the F atoms into the compsn of a ternary component system of CaO-Al2O3-P2O5. Further, the Li2O component is added to such compsn. to decrease the viscosity of the melt and to lower the softening point of the glassy casting and the crystallization temp. of calcium phosphate, by which the crystal of Al2O3.P2O5 is thoroughly developed and the difference in the specific gravity before and after the crystallization is eliminated to prevent the generation of the voids and cracks. This glass is adequate as the dental material such as artificial fang.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a cell that is stably supplied and induced to an osteoblast and to provide a method for forming an osteoblast by using the same.  &lt;P&gt;SOLUTION: The cell that exists in a human amniotic epithelial cell layer and is differentiated and induced into an osteoblast is obtained. The method for forming an osteoblast comprises culturing a cell contained in a human amniotic epithelial cell layer in an osteoblast differentiation medium and inducing an osteoblast. Since the cell is derived from a human amnion and the human amnion is a large tissue and is treated as a medical waste after childbirth, the human amnion is stably supplied. The cell or the osteoblast derived from it is transplanted to the deleted part of a bone to restore the bone.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The invention discloses an electronic device with a motion characterization circuitry. The electronic device may include a motion sensor for detecting movement of the electronic device. Applications that run on the electronic device such as fitness applications or activity logging applications may use motion sensor data to track a user&#39;s physical activity. To avoid mischaracterizing a user&#39;s movement, motion sensor circuitry in the electronic device may supplement motion sensor data with additional information in instances where motion sensor data alone may be insufficient to distinguish between different types of physical activity. For example, information on a user&#39;s speed may be synthesized with motion sensor data to help characterize a user&#39;s movement. Information on a user&#39;s speed may be determined based on location information. The location information may, for example, be gathered using IEEE 802.11 transceiver circuitry or, in more rural areas, may be gathered using Global Positioning System receiver circuitry.
The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient&#39;s breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release.
A pocket PC/desktop computer/PDA weight-training system designed to instantly calculate the domains of strength, power, endurance, work, aerobics, and body fat percentage. The system calculates the difference and percentage of change of each domain from weight-training session to session, reflecting a complete evaluation of overload. The system calculates the percentages of the user&#39;s 1-RM. When a weightlifting scheme grows ineffective, the user can choose another weight scheme related to their 1-RM, or they can change the exercises using a menu of complete exercises. The system also calculates the total rest days and days between trained body parts to evaluate recuperation cycles. The nutrition component calculates 47 nutrients, as the user marks servings of consumed foods. The user sets consumption goals, and the system reflects the difference of the goal and what was consumed. The aerobic/activity component gives the user a 30-day horizon analysis of muscle/fat gain or loss, based on the user&#39;s marked activity, calorie intake and the calculated basal metabolic rate.
The invention relates to corticotropin-B, its acid addition salts, to a polypeptide composition containing corticotropin-B and/or an ACTH-active derivative or corticotropin-B and to their production from pituitary gland material.  The crude material may be extracted with hydrochloric acid-acetone or methanolacetic acid and the extract contacted with oxycellulose in order to adsorb the ACTH-active substances thereon.  The oxycellulose adsorbate is eluted with a dilute mineral acid solution such as O-IN hydrochloric acid.  The pH of the eluate is adjusted to 2,5 to 3 by contacting it with a strongly basic anion exchange resin in its carbonate form and after removal of the resin by filtration the filtrate is concentrated.  The concentrate is digested with pepsin and treated with trichloracetic acid to precipitate substances of high molecular weight and low ACTH activity.  After clarification the aqueous solution is extracted with a water-immiscible organic solvent and then lyophilized.  The &#34;pepsin-digested material&#34; so obtained is passed in aqueous solution down a column of a carboxylic cation exchange resin such as a dihydroxybenzoic acid-formaldehyde condensate or a copolymer of a polymerizable acid and a divinyl compound such as acrylic or methacrylic acid and divinyl-benzene.  It is preferred to add a mild reducing agent such as hydrogen sulphide, sodium sulphite, thioglycollic acid or cysteine to the aqueous solution, and to use a resin in which about 15 per cent is in the sodium salt form, the remainder being the free-acid.  After washing the column, the resin adsorbate is eluted with aqueous mineral acid (HCC) of pH greater than 1,8 whereby low ACTH-active substances and substances of a lower basicity than corticotropin-B are removed. It is then eluted with aqueous mineral acid of pH from 0,0 to 1,8 whereby corticotropin-B and substances of similar basicity are removed from the resin. Lyophilization of this eluate gives a polypeptide composition containing corticotropin-B and having approximately 300 times the ACTH-activity of Armour Standard La-1-A.  Corticotropin-B may be separated from this composition by means of the Craig counter-current distribution procedure using the system s-butyl alcohol-0,5 per cent aqueous trichloracetic acid.  A detailed description of the complete procedure is given.
Parenterally administrable aqueous compositions comprise a compound of general formula &lt;FORM:0948582/A5-A6/1&gt; wherein n is an integer from 1 to 10 solubilized by a two component system of a condensation product of castor oil and ethylene oxide containing from about 20 to about 40 moles. of ethylene oxide per mole. of castor oil, and a water-miscible amide of the formula R-CO-NR1R11 wherein R is a hydrogen atom or a methyl radical, R1 is a hydrogen atom or a methyl or ethyl radical and R11 is a methyl or ethyl radical. Desirably the condensation product is used in amounts of from about 5 to about 25 mg. (preferably about 7 to about 15 mg.) per mg. of the active compound the amount of amide used being from 1.0 p  to 7.5% (V/V) of the total solution (preferably about 3.5 to about 5.5%). Conventional isotonicising agents and preservatives may also be present.  Specification 928,161 is referred to.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide polycyclic pyrimidines useful as a potassium ion channel controller.  &lt;P&gt;SOLUTION: The ion channel is a cellular protein that controls inflow into and outflow from a cell of ions containing calcium, potassium, sodium and chlorine. All of these channels exist in a human cell and exert influences on physiological processes such as nerve conduction, muscle contraction, cell secretion, control of heartbeat and artery extension. The potassium channel exists most widely and is diverse to be found in nerves, muscles, glands, immune systems and the like. A complex of a compound containing pyrimidine is provided as the channel controller.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The invention particularly relates to a traditional Chinese medicine pill for treating pathological fracture and a preparation method thereof. The traditional Chinese medicine pill for treating the pathological fracture contains 46 medicines, such as processed semen strychni, ginseng, scorpio, ephedra, frankincense, myrrh, Yurong powder, stiff silkworm, deer&#39;s sinew, notopterygium root, obscured homalomena rhizome, giantleaf ardisia rhizome, cortex acanthopanacis, radix scrophulariae, dried radix rehmanniae, dipsacus root, eucommia ulmoides oliv, taro pulp, morinda officinalis, white paeony root, the root of red-rooted salvia, bighead atractylodes rhizome, schisandra chinensis, fructus ligustri lucidi, fructus alpiniae oxyphyllae, moghania root, garter snake, glue of tortoise plastron, deerhorn glue, degelatinated deer antler, amber and the like. The processed semen strychni is smashed and shaped to obtain the traditional Chinese medicine pill. The traditional Chinese medicine pill for treating pathological fracture can treat various symptoms, such as waist disease, rheumatoid arthritis, hand and foot numbness, various nerve denervation symptoms, bone tumors, osteomyelitis, pathological paralysis, stroke paralysis and the like. The traditional Chinese medicine pill for treating pathological fracture has the advantages of no side effect, and obvious curative effect, and patients do not feel pain. The preparation method for the traditional Chinese medicine pill for treating pathological fracture has a simple technology and is easy to operate.
A method for improving intracellular translational efficiency and/or stability of RNA molecules. An RNA molecule preparation method is provided, comprising a step of adding a modified poly (A) sequence composed of a modified adenylic acid and an optional unmodified adenylic acid at the 3&#39; end of the poly (A) tail of a starting RNA molecule. The RNA molecule may be an mRNA molecule. Also provided are an RNA molecule, a pharmaceutical composition, a corresponding use, and a kit. The poly (A) tail of the RNA molecule prepared by the method is extended and has a modified adenylic acid at the extended portion. Compared with a starting RNA molecule without an extended poly (A) tail or an RNA molecule with an extended poly(A) tail that does not contain a modified adenylic acid, the present RNA molecule has improved intracellular translational efficiency and/or stability.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an ophthalmic composition such as an eye drop composition useful for the prevention, moderation and cure of dry eye symptom and an artificial tear liquid composition useful also as the artificial tear liquid.  &lt;P&gt;SOLUTION: This ophthalmic composition contains a poly-γ-glutamic acid as a component. The composition contains the poly-γ-glutamic acid in which the poly-γ-glutamic acid is an acid type, a salt type, a mixed type of the acid and salt types, a cross-linked type or a mixture of them, as its component, and further, may contain fructan and hyaluronic acid. Also, the poly-γ-glutamic acid has ≥30,000 molecular weight and is obtained from the culture of Natto bacillus. and it may contain a poly-γ-glutamic acid hyaluronic acid obtained by bonding the poly-γ-glutamic acid and hyaluronic acid. Also, the ophthalmic composition may be a contact lens-immersing liquid, ophthalmic gel or ophthalmic ointment.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE: To obtain a stable oil-in-water emulsion comprising a small quantity of an emulsifier by mixing a dispersion of metal oxide particles having a specified average primary particle size in an oil, an emulsifier and an aq. phase under such a condition to form a water-in-oil emulsion, wherein the emulsifier, the metal oxide particles, the oil phase and the aq. phase are used at the respective specified proportions. CONSTITUTION: A dispersion of metal oxide (such as titanium oxide) particles having an average primary particle size of &lt;0.2 μm in an oil, one or more emulsifiers (such as fatty acid) and an aq. phase are mixed under a such condition to form an water-in-oil emulsion. The total amount of the emulsifier present in the thus formed water-in-oil emulsion constitutes &lt;5 wt.%, the metal oxide particles constitutes 0.5-30 wt.% of the emulsion, the oil phase constitutes 10-60 wt.% of the emulsion and the aq. phase constitutes at least 40 wt.% of the emulsion. As a result, a stable water-in-oil emulsion comprising the less emulsifier than hitherto available ones can be obtained.